The disparity in survival outcomes between black and white women with breast cancer—the result of a complex interaction of biologic and nonbiologic factors—can be reduced by increasing access to health care in all U.S. states, researchers from the American Cancer Society concluded in a recent study.
In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of Galleri, the multi-cancer detection test from GRAIL Inc., to become the first multi-cancer detection test to receive regulatory approval.
